Navigation Links
Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
Date:8/23/2013

Jacksonville, FL and Savannah, GA (PRWEB) August 23, 2013

Morphogenesis Inc., a biotechnology firm that has developed a specialized process that educates the immune system to fight cancer in dogs, cats and horses, announces the start of a field study for its personalized cancer treatment for dogs in partnership with SEVO-Med (Southeastern Veterinary Oncology and Medicine).

Tampa-based Morphogenesis and SEVO-Med, a major southeastern veterinary oncology practice which has clinics in Jacksonville and Savannah, are providing the opportunity to pet owners and veterinarians to enroll dogs with High Grade B Cell Lymphoma who might benefit from this personalized treatment.

The first 20 dogs who qualify for the study will be selected. Veterinarians and dog owners who believe their patient/pet could qualify to participate in the study should immediately contact SEVO-Med at 904-278-3870 or 912-355-5791. Once a dog is accepted into the study, treatments and study tests are provided at no cost to the owner.

The vaccine-based cancer treatments developed by Morphogenesis have been shown to manage 17 types of cancer without any side effects in canine, feline and equine patients.

In the treatment developed by Morphogenesis, the dog’s own lymphoma cells undergo a marking process that helps the animal’s immune system recognize the cells as foreign and kill them.

“We educate the body’s immune system to fight its own tumor cells,” said Pat Lawman, Ph.D., CEO of Morphogenesis. “Our process helps keep the cancer in check so that it doesn't progress, and we all think that’s a win.”

“More and more, you are seeing companion animals present with all types of cancers,” Tracy LaDue, DVM, founder of SEVO-Med, wrote in letters to veterinarians informing them of this treatment option for qualifying dogs. “The study being conducted by Morphogenesis and SEVO-Med will further demonstrate the safety and effec
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
2. The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris
3. NYSCF scientists create personalized bone substitutes from skin cells
4. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
5. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
6. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
7. Transplanted brain cells in monkeys light up personalized therapy
8. Research and Markets: Personalized Medicine - Scientific and Commercial Aspects - 2013 Report
9. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences
10. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
11. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Pomerantz LLP is investigating claims on behalf of investors ... IPXL).  Such investors are advised to contact Robert ... ext. 237. The investigation concerns whether Impax ... Sections 10(b) and 20(a) of the Securities Exchange Act ... Impax Laboratories, Inc. (the "Company") issued a press release ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... July 29, 2014 TransVac Solutions, the ... collection and transport solutions for hospitals, will be exhibiting ... Engineering (ASHE) Annual Conference & Technical Exhibition Aug. 3-6 ... its technology for making hospitals cleaner, reducing infection risk ... the hospital’s life cycle. Staff will be available ...
(Date:7/29/2014)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) dramatically ... investment in Green Chemistry and donated more than 8,000 ... the Company announced Monday in its new 2013 ... The report comes in a year ... responsible corporate citizen, including recognition for the second consecutive ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... present during the 11th Annual BIO CEO & Investor,Conference ... The presentation,will be webcast from the Waldorf-Astoria Hotel ... To access the presentation via the Web, please go ...
... Feb. 3 Genomic Health,Inc. (Nasdaq: GHDX ) ... and year ended December 31, 2008. , ... to $31.2 million,compared with $19.3 million in the fourth quarter ... assay was $30.9 million in the fourth,quarter of 2008, an ...
... Feb. 3 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., ... has obtained CE Mark approval for its Neurostep(TM) ... system (CLS) used on peripheral nerves. CE Mark ... the Neurostep(TM) in any of the Member States ...
Cached Biology Technology:Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference 2Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3
(Date:7/29/2014)... an easier method to create DNAprotein conjugates. The ... diagnosing diseases. , DNA linked to proteins ... can be used in diagnostic techniques, nanotechnology and ... with DNA can be used for purposes ... biological material. The method also provides easier access ...
(Date:7/29/2014)... the University of Kent has shown for the first ... a breakthrough that could have a major impact on ... of Biosciences uncovered the mechanism whereby the physical properties ... actin filaments are ,fine-tuned, to undertake different functions. ... completely stable, providing a framework for the cell, others ...
(Date:7/29/2014)... to go and almost 2500 registered participants, the final ... The event, a joint venture between the Federation of ... for Biochemistry and Molecular Biology (SFBBM), will take place ... the Palais des Congrs in Paris, France. , The ... life sciences in Europe this year. It features more ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Counting down to FEBS-EMBO 2014 in Paris, France 2
... fattening than others? What about the risks of bariatric ... (ASN) on December 5-7 for answers to these questions ... Nutrition Conference. The 3-day program delivers valuable ... satellite sessions, and networking opportunities. Credentialed media, science writers ...
...   The Bensalem Township Police Department , in conjunction with ... of DNA testing.  This pilot program known as " BodeHITS ... kind in the country for law enforcement. Bensalem ... with over 6,000 DNA profiles consisting of evidence and reference/individual ...
... , Nov. 19, 2013 Nelson Laboratories ( www.nelsonlabs.com ... (#321) during BIOMEDevice in San ... Thor Rollins, biocompatibility specialist. Those interested in a consultation ... http://photos.prnewswire.com/prnh/20120727/LA47745LOGO ) Rollins will also present, ...
Cached Biology News:Advances and Controversies in Clinical Nutrition: Diet, Technology and Practice 290 Minute DNA Results, A First Of Its Kind, Coming To Bensalem 2Nelson Laboratories to Offer Free Biocompatibility Consultations During BIOMEDevice San Jose 2
Request Info...
... Universal Amplicon Detection Assay (ADA) ... the qualitative detection and quantitation ... in vitro nucleic acid amplification. ... to be used in diagnostic ...
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
... ready-to-use reagents for the isolation of genomic ... for the isolation of genomic DNA from ... for the isolation of genomic DNA from ... can be used for restriction endonuclease digestion ...
Biology Products: